16 septiembre 2015
Even patients with health insurance who have multiple myeloma may be vulnerable to “financial toxicity” because of the higher use of novel therapeutics and extended duration of myeloma treatment, researchers report.
http://www.sciencedaily.com/releases/2015/09/150916185109.htm
